Secondary Processes Dominate the Quiescent, Spontaneous Aggregation of α-Synuclein at Physiological pH with Sodium Salts

Robert I. Horne, Michael A. Metrick, Wing K. Man, Dillon J. Rinauro, Z. Faidon Brotzakis, Sean Chia, Georg Meisl, Michele VendruscoloACS 2023 · DOI

TL;DR

Researchers have developed a new in vitro assay that successfully mimics the spontaneous aggregation of alpha-synuclein (αS) at physiological pH, a crucial step for understanding Parkinson's disease. This assay, optimized with specific sodium salts and potassium ions, reveals that secondary nucleation processes, not primary ones, are the dominant drivers of aggregation under these conditions, offering a more physiologically relevant platform for drug discovery.

What Problem Does This Paper Address?

Parkinson's disease (PD) is characterized by the aggregation of the protein alpha-synuclein (αS) into toxic amyloid deposits. Developing effective treatments hinges on understanding this aggregation process, but accurately replicating it in laboratory settings has been a major hurdle. Current in vitro assays often require artificial conditions like the presence of lipid membranes or vigorous shaking to initiate αS aggregation within a reasonable timeframe. Furthermore, spontaneous aggregation and the critical secondary nucleation step (where new aggregates form from existing ones) are typically only observed at acidic pH levels (below 5.8), which doesn't reflect the physiological pH of the human body (around 7.4). This discrepancy limits the ability to test potential therapeutic compounds under conditions that closely mimic the disease environment.

Methods

The core of this work lies in optimizing in vitro assay conditions to achieve spontaneous, quiescent αS aggregation at physiological pH (7.4). The researchers systematically investigated the effects of various sodium salts, focusing on phosphate (NaPi), sulfate, and citrate, to identify those that could accelerate aggregation without external stimuli like shaking. They also explored the role of potassium ions (KCl), a major intracellular cation, in enhancing the reproducibility of the aggregation process.

To analyze the aggregation kinetics, they employed Thioflavin T (ThT) fluorescence measurements, a standard technique for detecting amyloid formation. By performing serial dilutions of αS monomer and varying seeding conditions (using pre-formed αS fibrils), they were able to dissect the contributions of different aggregation steps: primary nucleation (the initial formation of small aggregate seeds), elongation (growth of existing aggregates), and secondary nucleation. They used kinetic modeling, fitting the experimental data to established models, to quantify the rates of these processes and determine their dependence on αS monomer concentration.

To confirm the structural changes, they utilized Fourier Transform Infrared (FTIR) spectroscopy and Transmission Electron Microscopy (TEM) to characterize the formed αS fibrils. Finally, they validated their assay by testing known small molecule inhibitors of secondary nucleation, assessing their efficacy in slowing down the aggregation process under the newly established physiological conditions.

Datasets

Not discussed in the paper. The study focuses on generating and analyzing experimental data from in vitro aggregation assays.

Key Insights and Ideas

  • Physiological pH Aggregation Achieved: The most significant breakthrough is the development of an assay that reliably induces spontaneous αS aggregation at neutral pH (7.4) without the need for shaking or lipid membranes. This is a major step towards more relevant disease modeling.
  • Secondary Nucleation Dominance: Under these optimized conditions, the study strongly suggests that secondary nucleation is the primary driver of αS aggregation, rather than primary nucleation or elongation alone. This finding is crucial because secondary nucleation is thought to be a key amplification mechanism in vivo.
  • Salt and Ion Effects: Specific sodium salts, particularly sodium phosphate (NaPi), and the presence of potassium ions (KCl) were found to be critical for accelerating and stabilizing the quiescent aggregation process. This highlights the importance of ionic environment in protein aggregation.
  • Framework for Mechanistic Studies: The developed assay provides a robust platform for studying the mechanisms of αS aggregation and for screening potential therapeutic compounds, particularly those targeting secondary nucleation.
  • Inhibitor Validation: The successful inhibition of aggregation by known secondary nucleation inhibitors validates the assay's ability to capture this critical process and its potential for drug discovery.

Key Results

  • The use of 400 mM sodium phosphate (NaPi) and 150 mM potassium chloride (KCl) at pH 7.4 enabled quiescent, spontaneous αS aggregation within 1-2 days.
  • Kinetic analysis revealed that secondary nucleation processes were dominant and showed a weak dependence on αS monomer concentration, consistent with a scaling exponent close to -0.5.
  • Primary nucleation, in contrast, showed a strong dependence on monomer concentration, suggesting a high reaction order.
  • Small molecule inhibitors previously identified as targeting secondary nucleation effectively slowed down the aggregation in this new assay, confirming the mechanism.

Limitations and Future Work

  • Ex Vivo Replication: The authors acknowledge that it remains to be seen whether this in vitro assay can faithfully replicate ex vivo fibrils found in patient brains.
  • Cellular Ionic Concentrations: Future work aims to identify specific conditions and cofactors that would allow αS aggregation to occur at physiological pH with cellular ionic concentrations, further enhancing the physiological relevance.
  • Mechanism of Secondary Nucleation: While the dominance of secondary nucleation is established, the precise mechanism (e.g., fragmentation vs. secondary nucleation) could not be definitively determined from kinetics alone and may require further investigation.
  • Plateau Drift: The authors note that the slow approach to the plateau in kinetic curves, likely due to factors like clumping or sedimentation, complicates mechanistic analysis.

Summary updated

Abstract

The accurate recapitulation in an in vitro assay of the aggregation process of α-synuclein in Parkinson's disease has been a significant challenge. As α-synuclein does not aggregate spontaneously in most currently used in vitro assays, primary nucleation is triggered by the presence of surfaces such as lipid membranes or interfaces created by shaking, to achieve aggregation on accessible time scales. In addition, secondary nucleation is typically only observed by lowering the pH below 5.8. Here we investigated assay conditions that enables spontaneous primary nucleation and secondary nucleation at pH 7.4. Using 400 mM sodium phosphate, we observed quiescent spontaneous aggregation of α-synuclein and established that this aggregation is dominated by secondary processes. Furthermore, the presence of potassium ions enhanced the reproducibility of quiescent α-synuclein aggregation. This work provides a framework for the study of spontaneous α-synuclein aggregation at physiological pH.
BibTeX
@inproceedings{horne2023secondary,
  author = {Robert I. Horne and Michael A. Metrick and Wing K. Man and Dillon J. Rinauro and Z. Faidon Brotzakis and Sean Chia and Georg Meisl and Michele Vendruscolo},
  title = {{Secondary Processes Dominate the Quiescent, Spontaneous Aggregation of α-Synuclein at Physiological pH with Sodium Salts}},
  booktitle = {ACS},
  year = {2023},
  doi = {10.1021/acschemneuro.3c00282},
}
Figure